logo
  

Imugene In Deal With Merck KGaA, Pfizer To Evaluate HER-Vaxx - Avelumab For Gastric Cancer Treatment

Imugene (IMU.AX) said Wednesday that it has reached a new clinical trial supply agreement with Merck KgaA (MKGAY.PK) and Pfizer Inc. (PFE) to evaluate the safety and efficacy of Imugene's HER-Vaxx in combination with avelumab, an immune checkpoint inhibitor targeting PD-L1, in patients with HER-2 positive gastric cancer.

Imugene's HER-Vaxx is a B-cell peptide cancer immunotherapy designed to treat tumours that over-express the HER-2/neu receptor, such as gastric, breast, ovarian, lung and pancreatic cancers.

Avelumab, which is marketed as BAVENCIO, is co-developed and co-commercialized by Merck KgaA and Pfizer.

neoHERIZON, which is an open-label, multi-center, randomized, Phase 2 clinical trial, will assess the safety and efficacy of perioperative HER-Vaxx combined with chemotherapy with or without avelumab compared to chemotherapy alone in patients with HER-2 positive gastric or gastroesophageal junction adenocarcinomas.

As per the terms of the deal, Imugene will be the sponsor of the study and will fund the clinical study from existing budgets and resources. Merck KGaA and Pfizer will provide avelumab for the duration of the study.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Apple Inc. may face production shortfall of as many as 6 million iPhone Pro units this year due to ongoing protests at its major China plant, Bloomberg reported citing a person familiar with assembly operations. Following the news, Apple shares were losing around 2.2 percent in pre-market activity on the Nasdaq. Despite fears of inflation, consumers spent $9.12 billion for online shopping during Black Friday, higher than in previous years, as per a report published by Adobe Analytics. During the 2022 holiday season, total estimated revenues are $209.7 billion, a growth of 2.5 percent from last year's recorded revenues of $205 billion. Weis Markets, Inc., a Mid Atlantic food retailer, has recalled 108 containers of Weis Quality Sea Salt Caramel Ripple Ice Cream citing possible presence of undeclared soy and coconut allergens, the U.S. Food and Drug Administration said. The recalled product comes in 48oz containers that says Weis Quality Sea Salt Caramel Ripple Ice Cream, while the lid says Weis Quality Caramel Caribou Ice Cream
Follow RTT